Interleukin-6 mediates resistance to PI3K-pathway–targeted therapy in lymphoma

Interleukin-6 mediates resistance to PI3K-pathway–targeted therapy in lymphoma

Abstract Background The phosphoinositol 3-kinase (PI3K) pathway is associated with poor prognosis of hematologic malignancies, providing a strong rationale for the use of PI3K inhibitors in the treatment of malignant lymphoma. However, development of resistance limits the use of PI3K inhibitors in l...

Full description

Bibliographic Details
Main Authors: Joo Hyun Kim, Won Seog Kim, Chaehwa Park
Format: Article
Language:English
Published: BMC 2019-10-01
Series:BMC Cancer
Subjects:
Lymphoma
PI3K
Copanlisib
Duvelisib
Drug resistance
IL-6
Online Access:http://link.springer.com/article/10.1186/s12885-019-6057-7

Internet

http://link.springer.com/article/10.1186/s12885-019-6057-7

Similar Items